InMode Ltd. $INMD Shares Sold by Quantbot Technologies LP

Quantbot Technologies LP reduced its position in InMode Ltd. (NASDAQ:INMD) by 54.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,001 shares of the healthcare company’s stock after selling 98,763 shares during the period. Quantbot Technologies LP owned approximately 0.13% of InMode worth $1,237,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Villanova Investment Management Co LLC raised its holdings in InMode by 36.6% in the third quarter. Villanova Investment Management Co LLC now owns 101,714 shares of the healthcare company’s stock valued at $1,516,000 after buying an additional 27,258 shares during the period. GSA Capital Partners LLP increased its position in shares of InMode by 145.5% in the third quarter. GSA Capital Partners LLP now owns 26,752 shares of the healthcare company’s stock worth $399,000 after acquiring an additional 15,853 shares in the last quarter. Rothschild Investment LLC acquired a new stake in shares of InMode in the third quarter worth $85,000. State of New Jersey Common Pension Fund D raised its stake in shares of InMode by 612.1% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 96,120 shares of the healthcare company’s stock valued at $1,432,000 after acquiring an additional 82,621 shares during the period. Finally, Plan A Wealth LLC acquired a new position in shares of InMode during the 3rd quarter valued at $165,000. Hedge funds and other institutional investors own 68.04% of the company’s stock.

InMode Stock Performance

NASDAQ:INMD opened at $13.45 on Friday. The stock has a market cap of $852.19 million, a price-to-earnings ratio of 9.34 and a beta of 2.18. InMode Ltd. has a one year low of $13.14 and a one year high of $19.78. The business’s 50-day simple moving average is $14.59 and its 200 day simple moving average is $14.68.

InMode (NASDAQ:INMD) last posted its quarterly earnings data on Tuesday, February 10th. The healthcare company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.04. The company had revenue of $103.85 million for the quarter, compared to the consensus estimate of $104.64 million. InMode had a return on equity of 14.52% and a net margin of 25.33%.InMode’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.42 EPS. On average, equities research analysts predict that InMode Ltd. will post 1.75 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on INMD. Weiss Ratings reiterated a “sell (d+)” rating on shares of InMode in a report on Thursday, January 22nd. BTIG Research reaffirmed a “neutral” rating on shares of InMode in a research report on Monday, January 26th. Canaccord Genuity Group set a $15.00 target price on InMode and gave the company a “hold” rating in a research note on Wednesday, December 17th. Wall Street Zen downgraded InMode from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Robert W. Baird set a $17.00 price target on InMode in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $16.80.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.